MML Investors Services LLC Invests $204,000 in Cambrex Co. (CBM) Stock

MML Investors Services LLC bought a new position in shares of Cambrex Co. (NYSE:CBM) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 4,258 shares of the biotechnology company’s stock, valued at approximately $204,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of CBM. Brown Advisory Inc. increased its holdings in Cambrex by 454.1% during the fourth quarter. Brown Advisory Inc. now owns 895,240 shares of the biotechnology company’s stock worth $42,972,000 after buying an additional 733,663 shares during the last quarter. Lazard Asset Management LLC acquired a new position in Cambrex during the fourth quarter worth $22,203,000. Boston Partners increased its holdings in Cambrex by 118.5% during the fourth quarter. Boston Partners now owns 709,786 shares of the biotechnology company’s stock worth $34,069,000 after buying an additional 384,897 shares during the last quarter. Peregrine Capital Management LLC acquired a new position in Cambrex during the fourth quarter worth $9,780,000. Finally, Mackenzie Financial Corp acquired a new position in Cambrex during the fourth quarter worth $9,403,000.

How to Become a New Pot Stock Millionaire

CBM stock opened at $51.50 on Friday. Cambrex Co. has a 52-week low of $42.55 and a 52-week high of $62.95. The company has a market cap of $1,754.02, a price-to-earnings ratio of 16.78, a price-to-earnings-growth ratio of 1.27 and a beta of 2.38.

Cambrex (NYSE:CBM) last released its quarterly earnings data on Thursday, February 8th. The biotechnology company reported $1.27 EPS for the quarter, topping the Zacks’ consensus estimate of $1.10 by $0.17. Cambrex had a net margin of 19.17% and a return on equity of 22.42%. The firm had revenue of $182.28 million during the quarter, compared to analysts’ expectations of $181.39 million. During the same period in the previous year, the business posted $1.23 earnings per share. The company’s revenue for the quarter was up 2.5% compared to the same quarter last year. equities analysts predict that Cambrex Co. will post 2.81 EPS for the current fiscal year.

CBM has been the topic of a number of recent analyst reports. William Blair initiated coverage on shares of Cambrex in a report on Tuesday, January 16th. They set an “outperform” rating on the stock. Zacks Investment Research raised shares of Cambrex from a “strong sell” rating to a “hold” rating in a research report on Monday, January 15th. Finally, Longbow Research cut shares of Cambrex from a “buy” rating to a “neutral” rating in a research report on Wednesday, February 14th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $60.00.

WARNING: “MML Investors Services LLC Invests $204,000 in Cambrex Co. (CBM) Stock” was published by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another site, it was stolen and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3296402/mml-investors-services-llc-invests-204000-in-cambrex-co-cbm-stock.html.

About Cambrex

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Co. (NYSE:CBM).

Institutional Ownership by Quarter for Cambrex (NYSE:CBM)

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Pioneer Natural Resources to Post Q1 2018 Earnings of $1.54 Per Share, Piper Jaffray Forecasts
Pioneer Natural Resources to Post Q1 2018 Earnings of $1.54 Per Share, Piper Jaffray Forecasts
Novavax  Price Target Cut to $2.00
Novavax Price Target Cut to $2.00
Scorpio Tankers  Forecasted to Post Q1 2018 Earnings of  Per Share
Scorpio Tankers Forecasted to Post Q1 2018 Earnings of Per Share
PC Tel  Stock Rating Upgraded by Zacks Investment Research
PC Tel Stock Rating Upgraded by Zacks Investment Research
Zacks Investment Research Downgrades REGENXBIO  to Sell
Zacks Investment Research Downgrades REGENXBIO to Sell
HC Wainwright Reiterates “Buy” Rating for Synlogic
HC Wainwright Reiterates “Buy” Rating for Synlogic


© 2006-2018 Ticker Report. Google+.